2023 journal article

A randomised controlled trial testing the rebound‐preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis

Veterinary Dermatology.

By: T. Olivry n , V. Lokianskiene, A. Blanco, P. Mestre, K. Bergvall * & L. Beco

MeSH headings : Dogs; Animals; Dermatitis, Atopic / drug therapy; Dermatitis, Atopic / veterinary; Dermatitis, Atopic / complications; Prednisolone / therapeutic use; Dermatologic Agents; Pruritus / veterinary; Dog Diseases / pathology; Immunoglobulin A / therapeutic use
TL;DR: The initial addition of 4 days of prednisolone significantly decreased the probability of a rebound of pruritus 1 week after oclacitinib dose reduction, and this short concomitant glucocorticoid administration led to a higher skin lesion improvement and improved perception of treatment efficacy with minimal adverse effects. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Source: ORCID
Added: November 5, 2022

Abstract